Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy

To evaluate the short-term safety and efficacy of intravitreal bevacizumab for the treatment of intraretinal or subretinal fluid accumulation secondary to chronic central serous chorioretinopathy (CSC). Twelve patients were treated with intravitreal injections of 2.5 mg bevacizumab at 6- to 8-week i...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2009-07, Vol.19 (4), p.613-617
Main Authors: Schaal, Karen B, Hoeh, Alexandra E, Scheuerle, Alexander, Schuett, Florian, Dithmar, Stefan
Format: Article
Language:English
Subjects:
Adult
Aged
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Central Serous Chorioretinopathy - diagnosis
Central Serous Chorioretinopathy - drug therapy
Chronic Disease
Female
Fluorescein Angiography
Humans
Injections
Male
Middle Aged
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity
Vitreous Body
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the short-term safety and efficacy of intravitreal bevacizumab for the treatment of intraretinal or subretinal fluid accumulation secondary to chronic central serous chorioretinopathy (CSC). Twelve patients were treated with intravitreal injections of 2.5 mg bevacizumab at 6- to 8-week intervals until intraretinal or subretinal fluid resolved. Observation procedures were Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), ophthalmic examination, and optical coherence tomography (OCT), performed at 6- to 8-week intervals. Fluorescein angiography was performed at baseline visit and thereafter depending on clinical and OCT findings. Multivariate analysis of variance with repeated measures was used to calculate a statistical significance of change in BCVA and mean central retinal thickness, which were the main outcome measures. SAS statistical software was used for analyses. Patients received 2-/+1 intravitreal injections of bevacizumab on average during a follow-up of 24-/+14 weeks. Mean BCVA increased by 2-/+2 lines; the change in BCVA (logMAR) was significant (p
ISSN:1120-6721
1724-6016
DOI:10.1177/112067210901900415